Are biomarker changes preferable to clinical response as markers of treatment benefit? An evening debate.

Following a successful event in 2005, Breakthrough Breast Cancer and Breast Cancer Campaign will be holding another joint evening debate at the NCRI conference.

Entitled 'Biomarker changes are preferable to clinical response as markers of treatment benefit' and chaired by Mr Mike Dixon, with speakers Professor Mitch Dowsett and Professor Tony Howell, this years event promises to be just as successful.

It will take place at 8pm on Sunday 8th October.

Flyer for NCRI conference evening debate (846 kb)